Viewing Study NCT00666068


Ignite Creation Date: 2025-12-24 @ 5:43 PM
Ignite Modification Date: 2026-01-02 @ 8:36 AM
Study NCT ID: NCT00666068
Status: COMPLETED
Last Update Posted: 2011-05-12
First Post: 2008-04-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism
Sponsor: Max-Planck-Institute of Psychiatry
Organization:

Study Overview

Official Title: Effects of CRH on the Sleep in Patients With Hypopituitarism
Status: COMPLETED
Status Verified Date: 2011-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: In contrast to healthy subjects, patients with hypopituitarism do not exhibit endocrine responses when hormones are injected. This is at least true for those with a complete insufficiency of the anterior pituitary. For example, administration of corticotropin releasing hormone (CRH) is not followed by an increase of ACTH and cortisol. Therefore, "pure" hormone effects can be investigated.

It is well established that hormones of the hypothalamic-pituitary-adrenal axis are involved in sleep regulation. In rodents, CRH decreased slow wave sleep (SWS). In humans, CRH was reported to increase wakefulness and to decrease SWS and REM sleep. Primary objective was therefore to study the effect of CRH on patients with hypopituitarism.

To date, there is no information on sleep of patients with hypopituitarism. Secondary objective is therefore to compare sleep of patients with hypopituitarism with sleep of age-matched healthy controls.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: